OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
OPKO Health (Nasdaq: OPK) said its management team will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, held January 12-15, 2026. Management will host one-on-one investor meetings and take part in a fireside chat on Wednesday, January 14, 2026 at 1:30 p.m. PT. The fireside chat will be webcast live and available for replay in the Investors section of OPKO Health's website.
Positive
- None.
Negative
- None.
News Market Reaction – OPK
In the Jan 7 session, OPK gained 3.03%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 19 | Conference participation | Neutral | -0.8% | Piper Sandler healthcare conference attendance and investor meetings announcement. |
| Oct 29 | Earnings results | Neutral | +2.1% | Q3 2025 results with profit supported by oncology asset sale to Labcorp. |
| Oct 29 | Strategic partnership | Positive | -0.7% | ModeX collaboration with Regeneron using MSTAR platform and milestone economics. |
| Oct 28 | Clinical trial start | Positive | -0.7% | First patient dosed in Phase 1/2a trial of MDX2004 for advanced cancers. |
| Oct 22 | Earnings call notice | Neutral | +0.7% | Scheduling notice for Q3 2025 financial results release and conference call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent conference participation headlines have had modest price impact, while major strategic news (collaborations, trials, earnings) has sometimes seen price moves that diverge from the apparent positivity of the announcements.
Over the last few months, OPKO reported Q3 2025 results on October 29, 2025, highlighting $151.7M in revenue, positive operating income of $48.1M, and a significant asset sale to Labcorp. Around the same time, its ModeX unit began a Phase 1/2a trial for MDX2004 and entered a multispecific antibody collaboration with Regeneron valued at potentially over $1 billion. The company has also issued multiple conference participation notices, including Piper Sandler’s 37th Annual Healthcare Conference, similar in nature to today’s J.P. Morgan appearance update.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 44th Annual J.P. Morgan Healthcare Conference, being held January 12-15, 2026, at the Westin St. Francis Hotel in San Francisco. Management will be hosting one-on-one meetings with investors and will be participating in a fireside chat on Wednesday, January 14th at 1:30 p.m. Pacific time.
The fireside chat will be webcast live and available for replay in the Investors section of OPKO Health’s website here.
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.
Contacts:
Alliance Advisors IR
Yvonne Briggs, 310-691-7100
ybriggs@allianceadvisors.com
or
Bruce Voss, 310-691-7100
bvoss@allianceadvisors.com
